Taiwan Bio Therapeutics Co (ROCO:6892) EV-to-EBIT : -11.29 (As of May. 31, 2024)

Taiwan Bio Therapeutics Co EV-to-EBIT Chart

Competitive Comparison of Taiwan Bio Therapeutics Co's EV-to-EBIT

For the Biotechnology subindustry, Taiwan Bio Therapeutics Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Taiwan Bio Therapeutics Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Taiwan Bio Therapeutics Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Taiwan Bio Therapeutics Co's EV-to-EBIT falls into.

Taiwan Bio Therapeutics Co EV-to-EBIT Calculation

Taiwan Bio Therapeutics Co's EV-to-EBIT for today is calculated as:

Taiwan Bio Therapeutics Co's current Enterprise Value is NT$2,395.67 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Taiwan Bio Therapeutics Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-212.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taiwan Bio Therapeutics Co  (ROCO:6892) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Taiwan Bio Therapeutics Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Taiwan Bio Therapeutics Co's Enterprise Value for the quarter that ended in Dec. 2023 was NT$2,130.32 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Taiwan Bio Therapeutics Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-212.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taiwan Bio Therapeutics Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Taiwan Bio Therapeutics Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Taiwan Bio Therapeutics Co (ROCO:6892) Business Description